Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Mesoblast to be Added to Nasdaq Biotechnology Index
07:30am, Wednesday, 18'th Dec 2024
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
06:32pm, Wednesday, 04'th Dec 2024
Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pe
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
06:20pm, Monday, 02'nd Dec 2024
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Phase 3 trial results published in European Journal of Heart F
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
07:11pm, Wednesday, 30'th Oct 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
04:24pm, Monday, 30'th Sep 2024
Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate th
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
08:55pm, Sunday, 29'th Sep 2024
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a c
Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript
09:04pm, Wednesday, 28'th Aug 2024
Mesoblast Limited (NASDAQ:MESO ) Q4 2024 Earnings Conference Call August 28, 2024 6:30 PM ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Andrew Chaponnel - Inter
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
07:27pm, Wednesday, 28'th Aug 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and
Mesoblast Financial Results and Corporate Update Webcast
07:25pm, Tuesday, 27'th Aug 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
09:13pm, Tuesday, 30'th Jul 2024
Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD
If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Cell Therapy for Children Up To 18 Years Old with SR-aGVHD If Approved, RYONCIL will be
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
08:45pm, Sunday, 21'st Jul 2024
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Ph
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its B
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
09:40am, Tuesday, 02'nd Jul 2024
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
01:55am, Monday, 01'st Jul 2024
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Bi
